Feasibility, reliability, and clinical value of genomic assay on pre-therapeutic biopsy for endocrine receptor-positive HER2-negative early breast cancer
Given the feasibility and reliability of genomic assay on core needle biopsies, it can be suggested that this practice may become more common in the near future.